Identifies themes and clusters of stock movements
Market TodayThemes and Stocks SummaryThematic Stock SearchClick here for daily refresh schedule
PASG - Passage Bio Inc
$22.82
-4.49(-16.44%)9:00:00 PM 1/21/2021
Passage Bio, Inc., a genetic medicines company, focuses on developing transformative therapies for rare monogenic central nervous system (CNS) diseases. It has research, collaboration, and license agreement with the University of Pennsylvania and its gene therapy program; and The Trustees of the University of Pennsylvania for research and development collaborations, and exclusive license rights to patents for certain products and technologies. The company was founded in 2017 and is based in Philadelphia, Pennsylvania.
Stock Chart

Summary:

  • Price Zscore is at a recent 2 week low. A recent low ZScore means price drop is accelerating at a record speed.
  • Volume Zscore is a recent 2 week high. A recent surge of ZScore means trading activities is accelerating at a record speed.
  • Volatility is at a recent 2 week high. A high volatility of stock movement indicates uncertainty.

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Related Topics
leak data

Related Topics

Peers

Stock news

    01/19/2021PASG
    Passage Bio Announces Launch of Proposed Public Offering

    PHILADELPHIA, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system disorders, today announced that it has commenced an underwritten public offering of 7,000,000 shares of its common stock. All shares of common stock to be sold in the offering will be sold by Passage Bio. In addition, Passage Bio intends to grant the underwriters a 30-day option to purchase up to an ...

    01/19/2021PASG
    Passage Bio to Host First of a Series of 2021 Virtual R&D Events on January 25

    PHILADELPHIA, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced it will host a series of virtual Research & Development events in 2021, with the first one scheduled for Monday, January 25, 2021, 11 a.m. to 1 p.m. ET. The first event will focus on Passage Bio’s lead investigational therapy PBGM01 and its disease target, infantile GM1 ga...

    01/13/2021PASG
    J.P. Morgan Predicts 30%-Plus Rally for These 2 Stocks

    Basic physics, and the evidence of our own eyes, tells us that what goes up must come down. But the NASDAQ is over 13,000, and the S&P 500 is over 3,800, and some market watchers are starting to wonder where the ceiling is. Banking giant JPMorgan investigates that question, seeking to find out just how much room the bulls have left to run in the current market conditions.Looking back to the collapse of Lehman Brothers, and the financial crisis of 2008, the bank’s global markets strategist Nikola...

    01/11/2021PASG
    Passage Bio Announces Plan to Deliver on Multiple Meaningful Catalysts in 2021

    – Investigational New Drug Applications (IND) submitted for PBFT02 for Frontotemporal Dementia with Granulin Mutation (FTD-GRN) and PBKR03 for Krabbe Disease –– Three clinical programs to begin in 1H21 –– Metachromatic leukodystrophy program, PBML04, advanced to IND-enabling phase –– Additional option exercised from Penn’s world-class Gene Therapy Program for undisclosed program focused on an adult CNS disorder –– New manufacturing laboratory to support analytical capabilities, clinical product ...

    01/4/2021PASG
    Passage Bio to Present at the 39th Annual J.P. Morgan Healthcare Conference

    PHILADELPHIA, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that Bruce Goldsmith, Ph.D., president and chief executive officer will present a company overview at the J.P Morgan 39th Annual Healthcare Conference being held virtually on Monday, January 11, 2021 at 7:30am ET. A live webcast of the presentation will be available on th...

    01/4/2021PASG
    Passage Bio Receives FDA Clearance of IND Application for Lead Gene Therapy Candidate PBGM01 for Treatment of Infantile GM1 Gangliosidosis

    FDA clearance marks second regulatory authorization for global Phase 1/2 clinical trial, Imagine-1 study, expected to dose first patient in first quarter 2021PHILADELPHIA, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system (CNS) disorders, today announced that U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for the...

    12/16/2020PASG
    Passage Bio Announces Gene Therapy Manufacturing Research and Development Site

    \- Company invests to build in-house capabilities to support advancement of pipeline - \- In combination with dedicated CGMP suite at Catalent, the new laboratory creates foundation for integrated AAV gene therapy manufacturing -PHILADELPHIA, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system (CNS) disorders, today announced that it has entered into a long-term ...

    12/16/2020PASG
    Is PASG A Good Stock To Buy Now?

    Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another high in recent weeks. On the other hand, technology hedge funds weren’t timid and registered double digit market beating gains. Financials, energy and industrial stocks aren’t doing […]